Arbutus Biopharma Corp Goodwill, Impairment Loss, Net of Tax
Arbutus Biopharma Corp (ABUS) reported Goodwill, Impairment Loss, Net of Tax of $22.50 million for the 3-month period ending 2019-09-30, per its 10-K filed 2020-03-05.
Discontinued › Expense Statement › Operating Expenses
us-gaap:GoodwillImpairmentLossNetOfTax · last filed 2020-03-05
- Arbutus Biopharma Corp goodwill, impairment loss, net of tax for the quarter ending 2019-09-30 was $22.50M.
| Period end | Goodwill, Impairment Loss, Net of Tax 3 month |
|---|---|
| 2019-09-30 | $22.50M 10-K · filed 2020-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |